A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study

Y. Chiu, C. Tang, S. Hung, Y. Yang, C. Fang, H. Lin

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Fingerprint

Dive into the research topics of 'A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study'. Together they form a unique fingerprint.

Medicine & Life Sciences